Literature DB >> 31864895

Clinical and Preclinical Imaging of Hepatosplenic Schistosomiasis.

Brice Masi1, Teodora-Adriana Perles-Barbacaru2, Monique Bernard1, Angèle Viola3.   

Abstract

Schistosomiasis, a neglected tropical disease, is a major cause of chronic morbidity and disability, and premature death. The hepatosplenic form of schistosomiasis is characterized by hepatosplenomegaly, liver fibrosis, portal hypertension, and esophageal varices, whose rupture may cause bleeding and death. We review currently available abdominal imaging modalities and describe their basic principles, strengths, weaknesses, and usefulness in the assessment of hepatosplenic schistosomiasis (HSS). Advanced imaging methods are presented that could be of interest for hepatosplenic schistosomiasis evaluation by yielding morphological, functional, and molecular parameters of disease progression. We also provide a comprehensive view of preclinical imaging studies and current research objectives such as parasite visualization in hosts, follow-up of the host's immune response, and development of noninvasive quantitative methods for liver fibrosis assessment.
Copyright © 2019 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  clinical imaging; hepatosplenic schistosomiasis; liver fibrosis; portal hypertension; preclinical imaging; quantitative imaging methods

Mesh:

Year:  2019        PMID: 31864895     DOI: 10.1016/j.pt.2019.11.007

Source DB:  PubMed          Journal:  Trends Parasitol        ISSN: 1471-4922


  7 in total

1.  Single oral fixed-dose praziquantel-miltefosine nanocombination for effective control of experimental schistosomiasis mansoni.

Authors:  Maha M Eissa; Mervat Z El-Azzouni; Labiba K El-Khordagui; Amany Abdel Bary; Riham M El-Moslemany; Sara A Abdel Salam
Journal:  Parasit Vectors       Date:  2020-09-15       Impact factor: 3.876

Review 2.  Schistosomiasis Pulmonary Arterial Hypertension.

Authors:  Jean Pierre Sibomana; Aloma Campeche; Roberto J Carvalho-Filho; Ricardo Amorim Correa; Helena Duani; Virginia Pacheco Guimaraes; Joan F Hilton; Biruk Kassa; Rahul Kumar; Michael H Lee; Camila M C Loureiro; Sula Mazimba; Claudia Mickael; Rudolf K F Oliveira; Jaquelina S Ota-Arakaki; Camila Farnese Rezende; Luciana C S Silva; Edford Sinkala; Hanan Yusuf Ahmed; Brian B Graham
Journal:  Front Immunol       Date:  2020-12-10       Impact factor: 7.561

3.  Prediction of minimal hepatic encephalopathy by using an radiomics nomogram in chronic hepatic schistosomiasis patients.

Authors:  Ying Li; Shuai Ju; Xin Li; Yan Li Zhou; Jin Wei Qiang
Journal:  PLoS Negl Trop Dis       Date:  2021-10-15

4.  Synergistic effect of combination chemotherapy with praziquantel and DW-3-15 for Schistosoma japonicum in vitro and in vivo.

Authors:  Zi-Yin Yang; Zi-Hao Liu; Ya-Nan Zhang; Chen Li; Lei Liu; Wen-Jie Pu; Shi-Qi Xie; Jing Xu; Chao-Ming Xia
Journal:  Parasit Vectors       Date:  2021-10-26       Impact factor: 3.876

5.  Experimental Schistosoma japonicum-induced pulmonary hypertension.

Authors:  Biruk Kassa; Michael H Lee; Rahul Kumar; Claudia Mickael; Linda Sanders; Rubin M Tuder; Margaret Mentink-Kane; Brian B Graham
Journal:  PLoS Negl Trop Dis       Date:  2022-04-13

6.  Inhibition of COX-2 ameliorates murine liver schistosomiasis japonica through splenic cellular immunoregulation.

Authors:  Zhang Qi; Chen Lan; Ji Xiaofang; Tang Juanjuan; Fu Cheng; Huang Ting; Shen Erxia; Li Zi
Journal:  Parasit Vectors       Date:  2022-04-23       Impact factor: 4.047

7.  Serum proteomic profiling in patients with advanced Schistosoma japonicum-induced hepatic fibrosis.

Authors:  Jing Huang; Xinguang Yin; Lifang Zhang; Ming Yao; Dahai Wei; Yiming Wu
Journal:  Parasit Vectors       Date:  2021-05-01       Impact factor: 4.047

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.